Trials / Recruiting
RecruitingNCT06174766
A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 324 (estimated)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGP2102-1 | Test drug |
| DRUG | HGP2102-2 | Test drug |
| DRUG | RLD2209-1 | Control drug |
| DRUG | RLD2209-2 | Control drug |
Timeline
- Start date
- 2024-05-10
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2023-12-18
- Last updated
- 2025-06-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06174766. Inclusion in this directory is not an endorsement.